Byotrol PLC - Chester, England-based manufacturer of biocidal and antimicrobial cleaning products - Reiterates its results for the year ending March 31 are in line with its expectations for sales of GBP.46 million and earnings before interest, tax, depreciation and amortisation loss of GBP700,000. Adds its operating strategy remains unchanged as it focuses on achieving regulatory approval for its Cruise platform across Europe by early 2025. It also confirms "good progress" in its new Anigene and Chemgene MedLab formulations, as well as its Cruise technology platform. Nevertheless, says revenue has fallen behind expectations due to slower growth in product sales as well as the discontinuation of legacy products.
Current stock price: 1.60 pence, down 8.6% on Thursday
12-month change: down 40%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
